Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy

Kura Oncology has spun out Caspian Therapeutics with $50 million in backing, including Eli Lilly, to develop KO-7246, a next-generation menin inhibitor for diabetes, advancing preclinical and clinical studies beyond oncology applications.

This Wire brief sits within Fusion42's coverage of Biotech.